Calcineurin Inhibitor Toxicity in Solid Organ Transplantation Available to Purchase

2.

Keogh

A

.

Calcineurin inhibitors in heart transplantation

.

J. Heart Lung Transplant

.

2004 May 1

;

23

(

5

):

S202

–

6

.

3.

Hume

DM

,

Merrill

JP

,

Miller

BF

,

Thorn

GW

.

Experiences with renal homotransplantation in the human: report of nine cases

.

J Clin Invest

.

1955

;

34

(

2

):

327

–

82

.

4.

Tanaka

H

.

Serological typing of HLA. Rinsho byori

.

JPN J Clin Oncol

.

1999

.

5.

Casey

MJ

,

Meier-Kriesche

H-U

.

Calcineurin inhibitors in kidney transplantation: friend or foe

.

Curr Opin Nephrol Hypertens

.

2011

.

6.

Magnone

M

.

Expanding the kidney allograft donor pool in the tacrolimus era

.

Surg Technol Int

.

1995

;

IV

:

301

–

3

.

7.

Stein

DP

,

Lederman

RJ

,

Vogt

DP

,

Carey

WD

,

Broughan

T

.

Neurological complications following liver transplantation

.

Ann Neurol

.

1992

;

31

(

6

):

644

–

9

.

8.

Myers

BD

,

Ross

J

,

Newton

L

,

Luetscher

J

,

Perlroth

M

.

Cyclosporine-associated chronic nephropathy

.

N Engl J Med

.

1984

;

311

(

11

):

699

–

705

.

9.

Nankivell

BJ

,

Borrows

RJ

,

Fung

CLS

,

O’Connell

PJ

,

Allen

RDM

,

Chapman

JR

.

The natural history of chronic allograft nephropathy

.

N Engl J Med

.

2003

;

349

(

24

):

2326

–

33

.

10.

Ojo

AO

,

Held

PJ

,

Port

FK

,

Wolfe

RA

,

Leichtman

AB

,

Young

EW

, .

Chronic renal failure after transplantation of a nonrenal organ

.

N Engl J Med

.

2003

;

349

(

10

):

931

–

40

.

11.

Marcén

R

,

Morales

JM

,

Fernández-Rodriguez

A

,

Capdevila

L

,

Pallardó

L

,

Plaza

JJ

, .

Long-term graft function changes in kidney transplant recipients

.

NDT Plus

.

2010

;

3

(

Suppl 2

):

ii2

.

12.

Ekberg

H

,

Tedesco-Silva

H

,

Demirbas

A

,

Vítko

Š

,

Nashan

B

,

Gürkan

A

, .

Reduced exposure to calcineurin inhibitors in renal transplantation

.

N Engl J Med

.

2007 Dec 20

;

357

(

25

):

2562

–

75

.

13.

Stegall

MD

,

Cornell

LD

,

Park

WD

,

Smith

BH

,

Cosio

FG

.

Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury

.

Am J Transplant

.

2018

;

18

(

1

):

180

–

8

.

14.

Baraldo

M

.

Meltdose tacrolimus pharmacokinetics

.

Transplant Proc

.

2016

;

48

(

2

):

420

.

15.

Tremblay

S

,

Nigro

V

,

Weinberg

J

,

Woodle

ES

,

Alloway

RR

.

A steady-state head-to-head pharmacokinetic comparison of all fk-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study

.

Am J Transplant

.

2017

;

17

(

2

):

432

–

42

.

16.

Budde

K

,

Bunnapradist

S

,

Grinyo

JM

,

Ciechanowski

K

,

Denny

JE

,

Silva

HT

, .

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial

.

Am J Transplant

.

2014

;

14

(

12

):

2796

–

806

.

17.

Bunnapradist

S

,

Ciechanowski

K

,

West-Thielke

P

,

Mulgaonkar

S

,

Rostaing

L

,

Vasudev

B

, .

Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial

.

Am J Transplant

.

2013

;

13

(

3

):

760

–

9

.

18.

Slatinska

J

,

Rohal

T

,

Wohlfahrtova

M

,

Viklicky

O

.

Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: A large single-center experience

.

Transplantation proceedings [Internet]

.

Transplant Proc

;

2013

. p.

1491

–

6

. Available from: https://pubmed.ncbi.nlm.nih.gov/23726604/

19.

Tedesco Silva

H

.

The long journey of mtor inhibitors and the long path that is still ahead

.

Transplantation

.

2018 Feb 1

;

102

(

Suppl 1

):

S1

–

2

. Available from: http://journals.lww.com/00007890-201802001-00001

20.

Ekberg

H

,

Tedesco-Silva

H

,

Demirbas

A

,

Vítko

Š

,

Nashan

B

,

Gürkan

A

, .

Reduced exposure to calcineurin inhibitors in renal transplantation

.

N Engl J Med

.

2007 Dec 20

;

357

(

25

):

2562

–

75

.

21.

Flechner

SM

,

Glyda

M

,

Cockfield

S

,

Grinyõ

J

,

Legendre

C

,

Russ

G

, .

The orion study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

.

Am J Transplant

.

2011

.

22.

Flechner

SM

,

Gurkan

A

,

Hartmann

A

,

Legendre

CM

,

Russ

GR

,

Campistol

JM

, .

A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients

.

Transplantation

.

2013

.

23.

Lebranchu

Y

,

Thierry

A

,

Toupance

O

,

Westeel

PF

,

Etienne

I

,

Thervet

E

, .

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study

.

Am J Transplant

.

2009

.

24.

Schena

FP

,

Pascoe

MD

,

Alberu

J

,

Del Carmen Rial

M

,

Oberbauer

R

,

Brennan

DC

, .

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

.

Transplantation

.

2009

.

25.

Holdaas

H

,

Rostaing

L

,

Serón

D

,

Cole

E

,

Chapman

J

,

Fellstrøm

B

, .

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study

.

Transplantation

.

2011

.

26.

Pascual

J

,

Berger

SP

,

Witzke

O

,

Tedesco

H

,

Mulgaonkar

S

,

Qazi

Y

, .

Everolimus with reduced calcineurin inhibitor exposure in renal transplantation

.

J Am Soc Nephrol

.

2018

.

27.

Berger

SP

,

Sommerer

C

,

Witzke

O

,

Tedesco

H

,

Chadban

S

,

Mulgaonkar

S

, .

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

.

Am J Transplant

.

2019

.

28.

Larsen

CP

,

Pearson

TC

,

Adams

AB

,

Tso

P

,

Shirasugi

N

,

Strobert

E

, .

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties

.

Am J Transplant

.

2005

.

29.

Vincenti

F

,

Larsen

C

,

Durrbach

A

,

Wekerle

T

,

Nashan

B

,

Blancho

G

, .

Costimulation Blockade with Belatacept in Renal Transplantation

.

N Engl J Med

.

2005 Aug 25

;

353

(

8

):

770

–

81

.

30.

Vincenti

F

,

Charpentier

B

,

Vanrenterghem

Y

,

Rostaing

L

,

Bresnahan

B

,

Darji

P

, .

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study)

.

Am J Transplant

.

2010

;

10

(

3

):

535

.

31.

Vincenti

F

,

Rostaing

L

,

Grinyo

J

,

Rice

K

,

Steinberg

S

,

Gaite

L

, .

Belatacept and long-term outcomes in kidney transplantation

.

N Engl J Med

.

2016

;

374

(

4

):

333

.

32.

Durrbach

A

,

Pestana

JM

,

Pearson

T

,

Vincenti

F

,

Garcia

VD

,

Campistol

J

, .

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study)

.

Am J Transplant

.

2010 Mar

;

10

(

3

):

547

–

57

.

33.

Wojciechowski

D

,

Vincenti

F

.

Current status of costimulatory blockade in renal transplantation

.

Curr Opin Nephrol Hypertens

.

2016

;

25

(

6

):

583

.

34.

Cordoba

F

,

Wieczorek

G

,

Audet

M

,

Roth

L

,

Schneider

MA

,

Kunkler

A

, .

A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion

.

Am J Transplant

.

2015

;

15

(

11

):

2825

.

35.

Vincenti

F

.

New monoclonal antibodies in renal transplantation

.

Minerva Urol Nefrol

.

2003

;

55

(

1

):

57

.

36.

Nashan

B

,

Tedesco

H

,

Van Den Hoogen

M

,

Berger

S

,

Cibrik

D

,

Mulgaonkar

S

, .

CFZ533, a new anti-CD40 mab demonstrates comparable efficacy and better renal function versus tacrolimus in de-novo CNI-free kidney transplantation

.

Am J Transplant

.

2018

.

37.

Espié

P

,

He

Y

,

Koo

P

,

Sickert

D

,

Dupuy

C

,

Chokoté

E

, .

First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody

.

Am J Transplant

.

2020 Feb 6

;

20

(

2

):

463

–

73

.

38.

Albach

FN

,

Wagner

F

,

Hüser

A

,

Igel

J

,

Joseph

D

,

Hilbert

J

, .

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

.

Eur J Clin Pharmacol

.

2018

;

74

(

2

):

161

–

9

.

39.

Goldwater

R

,

Keirns

J

,

Blahunka

P

,

First

R

,

Sawamoto

T

,

Zhang

W

, .

A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects

.

Am J Transplant

.

2013

;

13

(

4

):

1040

.

40.

Ristov

J

,

Espie

P

,

Ulrich

P

,

Sickert

D

,

Flandre

T

,

Dimitrova

M

, .

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody

.

Am J Transplant

.

2018

;

18

(

12

):

2895

.

41.

Haas

M

.

The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts

.

Am J Transplant

.

2018

;

18

(

12

):

2849

.

42.

Myers

BD

,

Newton

L

.

Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury

.

J Am Soc Nephrol

.

1991

;

2

(

2 Suppl 1

):

S45

.

43.

Mohan

S

,

Campenot

E

,

Chiles

MC

,

Santoriello

D

,

Bland

E

,

Crew

RJ

, .

Association between reperfusion renal allograft biopsy findings and transplant outcomes

.

J Am Soc Nephrol

.

2017

;

28

(

10

):

3109

.

44.

Baan

CC

,

Balk

AHMM

,

Holweg

CTJ

,

Van Riemsdijk

IC

,

Maat

LPWM

,

Vantrimpont

PJMJ

, .

Renal failure after clinical heart transplantation is associated with the TGF-β1 codon 10 gene polymorphism

.

J Hear Lung Transplant

.

2000

;

23

(

2

):

171

.

45.

Xia

T

,

Zhu

S

,

Wen

Y

,

Gao

S

,

Li

M

,

Tao

X

, .

Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis

.

Drug Des Devel Ther

.

2018

;

12

:

417

.

46.

Einecke

G

,

Reeve

J

,

Halloran

PF

.

Hyalinosis lesions in renal transplant biopsies: time-dependent complexity of interpretation

.

Am J Transplant

.

2017 May 1

;

17

(

5

):

1346

–

57

.

47.

Halloran

PF

,

Reeve

J

,

Akalin

E

,

Aubert

O

,

Bohmig

GA

,

Brennan

D

, .

Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study

.

Am J Transplant

.

2017

;

17

(

11

):

2851

.

48.

Murray

BM

,

Paller

MS

,

Ferris

TF

.

Effect of cyclosporine administration on renal hemodynamics in conscious rats

.

Kidney Int

.

1985

;

28

(

5

):

767

–

74

.

49.

Dieperink

H

,

Starklint

H

,

Leyssac

PP

.

Nephrotoxicity of cyclosporine. An animal model: study of the nephrotoxic effect of cyclosporine on overall renal and tubular function in conscious rats

.

Transplant Proc

.

1983

.

50.

Olyaei

AJ

,

De Mattos

AM

,

Bennett

WM

.

Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies

.

Curr Opin Crit Care

.

2001

;

7

(

6

):

384

.

51.

Burdmann

EA

,

Andoh

TF

,

Yu

L

,

Bennett

WM

.

Cyclosporine nephrotoxicity

.

Semin Nephrol

.

2003

;

23

(

5

):

465

–

76

.

52.

Takeda

Y

,

Miyamori

I

,

Wu

P

,

Yoneda

T

,

Furukawa

K

,

Takeda

R

.

Effects of an endothelin receptor antagonist in rats with cyclosporine- induced hypertension

.

Hypertension

.

1995

.

53.

Cediel

E

,

va zquez-Cruz

B

,

Navarro-Cid

J

,

De

N

,

Heras

L

,

Sanz-Rosa

D

, .

Role of endothelin-1 and thromboxane A 2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension

.

Kidney Int Suppl

.

2002

.

54.

Oriji

GK

,

Keiser

HR

.

Nitric oxide in cyclosporine A-induced hypertension: role of protein kinase C

.

Am J Hypertens

.

1999

.

55.

Guidi

E

,

Minetti

EE

,

Cozzi

MG

.

Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies

.

J Renin Angiotensin Aldosterone Syst

.

2002

;

3

(

1

):

40

.

56.

Wu

Z

,

Zhang

H

,

Jin

W

,

Liu

Y

,

Lu

L

,

Chen

Q

, .

The effect of renin-angiotensin-aldosterone system blockade medications on contrast- induced nephropathy in patients undergoing coronary angiography: a meta-analysis

.

PLoS One

.

2015

.

57.

Franz

M

,

Regele

H

,

Schmaldienst

S

,

Stummvoll

HK

,

Hörl

WH

,

Pohanka

E

.

Postransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients. Advantage of FK506 therapy

.

Transplantation

.

1998

.

58.

Noris

M

,

Remuzzi

G

.

Thrombotic microangiopathy after kidney transplantation

.

Am J Transplant

.

2010

;

10

(

7

):

1517

.

59.

Yango

A

,

Morrissey

P

,

Monaco

A

,

Butera

J

,

Gohh

RY

.

Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange [1]

.

Clin Nephrol

.

2002

;

58

(

1

):

77

.

60.

Abbas

F

,

Kossi

E

,

Kim

JJ

,

Sharma

A

,

Halawa

A

.

Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease

.

World J Transplant

.

2018

;

8

(

5

):

122

–

41

.

61.

Randhawa

PS

,

Starzl

TE

,

Demetris

AJ

.

Tacrolimus (FK506)-Associated Renal Pathology

.

Adv Anat Pathol

.

1997

;

4

(

4

):

265

–

76

.

62.

Stillman

IE

,

Brezis

M

,

Heyman

SN

,

Epstein

FH

,

Spokes

K

,

Rosen

S

.

Effects of salt depletion on the kidney: changes in medullary oxygenation and thick ascending limb size

.

J Am Soc Nephrol

.

1994

;

4

(

8

):

1538

.

63.

Rosen

S

,

Greenfeld

Z

,

Brezis

M

.

Chronic cyclosporine-induced nephropathy in the rat: a medullary ray inner stripe injury

.

Transplantation

.

1990

;

49

(

2

):

445

–

52

.

64.

Cippà

PE

,

Grebe

SO

,

Fehr

T

,

Wüthrich

RP

,

Mueller

TF

.

Altitude and arteriolar hyalinosis after kidney transplantation

.

Nephrology

.

2016

.

65.

Fertin

C

,

Nicolas

JF

,

Gillery

P

,

Kalis

B

,

Banchereau

J

,

Maquart

FX

.

Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents

.

Cell Mol Biol

.

1991

.

66.

Pohlers

D

,

Brenmoehl

J

,

Löffler

I

,

Müller

CK

,

Leipner

C

,

Schultze-Mosgau

S

, .

TGF-β and fibrosis in different organs – molecular pathway imprints

.

Biochim Biophys Acta

.

2009

;

1792

(

8

):

746

.

67.

Faler

BJ

,

Macsata

RA

,

Plummer

D

,

Mishra

L

,

Sidawy

AN

.

Transforming growth factor-β and wound healing

.

Perspect Vasc Surg Endovasc Ther

.

2006

.

68.

Shin

GT

,

Khanna

A

,

Sharma

VK

,

Ding

R

,

Azizlerli

S

,

Li

B

, .

In vivo hyperexpression of transforming growth factor-β1 in humans: stimulation by cyclosporine

.

Transplant Proceedings

.

1997

.

69.

Mohamed

MAS

,

Robertson

H

,

Booth

TA

,

Balupuri

S

,

Kirby

JA

,

Talbot

D

.

TGF-β expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus

.

Transplantation

.

2000

.

70.

Kalluri

R

,

Neilson

EG

.

Epithelial-mesenchymal transition and its implications for fibrosis

.

Clin Invest

.

2003

;

112

(

12

):

1776

.

71.

Baczkowska

T

,

Perkowska-Ptasińska

A

,

Lewandowski

Z

,

Nowacka-Cieciura

E

,

Cieciura

T

,

Pazik

J

, .

Serum TGF-β1 correlates with chronic histopathological lesiones in protocol biopsies in kidney allograft recipients

.

Transplantation

.

2004

.

72.

Burkly

LC

.

TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities

.

Semin Immunol

.

2014

;

26

(

3

):

229

.

73.

Claus

M

,

Herro

R

,

Wolf

D

,

Buscher

K

,

Rudloff

S

,

Huynh-Do

U

, .

The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys

.

Am J Transplant

.

2018

;

18

(

7

):

1636

.

74.

Portilla

D

.

Apoptosis, fibrosis and senescence

.

Neph Clin Prac

.

2014

.

75.

Thomas

DM

,

Coles

GA

,

Williams

JD

.

What does the renal reserve mean

.

Kidney Int

.

1994

.

76.

Rabe

M

,

Schaefer

F

.

Non-transgenic mouse models of kidney disease

.

Nephron

.

2016 Jun 1

;

133

(

1

):

53

–

61

.

77.

Andoh

TF

,

Johnson

RJ

,

Lam

T

,

Bennett

WM

.

Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension

.

Am J Transplant

.

2001 Sep 1

;

1

(

3

):

222

–

7

.

78.

Pere

AK

,

Lindgren

L

,

Tuomainen

P

,

Krogerus

L

,

Rauhala

P

,

Laakso

J

, .

Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity

.

Kidney Int

.

2000

.

79.

Fujita

T

,

Ando

K

.

Hemodynamic and endocrine changes associated with potassium supplementation in sodium-loaded hypertensives

.

Hypertension

.

1984

.

80.

Nagai

I

,

Gebrewold

A

,

Altura

BT

,

Altura

BM

.

Magnesium salts exert direct vasodilator effects on rat cremaster muscle microcirculation

.

Arch Int Pharmacodyn Ther

.

1988

.

81.

Nishio

A

,

Grebrewold

A

,

Altura

BT

,

Altura

BM

.

Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules

.

Arch Int Pharmacodyn Ther

.

1989

.

82.

Kirk

AJB

,

Omar

I

,

Dark

JH

.

Long-term improvement in renal function using nifedipine in cyclosporine-associated hypertension

.

Transplantation [Internet]

.

1990

;

50

(

6

):

1061

.

83.

Ruggenenti

P

,

Perico

N

,

Mosconi

L

,

Gaspari

F

,

Benigni

A

,

Amuchastegui

CS

, .

Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion

.

Kidney Int

.

1993

;

43

(

3

):

706

–

11

.

84.

Weinrauch

LA

,

Liu

J

,

Claggett

B

,

Finn

PV

,

Weir

MR

,

D’Elia

JA

.

Calcium channel blockade and survival in recipients of successful renal transplant: An analysis of the FAVORIT trial results

.

Int J Nephrol Renovasc Dis

.

2018

;

11

:

1

–

7

.

85.

van Riemsdijk

IC

,

Mulder

PG

,

de Fijter

JW

,

Bruijn

JA

,

van Hooff

JP

,

Hoitsma

AJ

, .

Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study

.

Transplantation

.

2000 Jul 15

;

70

(

1

):

122

–

6

.

86.

Paul

M

,

Ganten

D

.

The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system

.

J Cardiovasc Pharmacol

.

1992

.

87.

Thomsen Nielsen

F

,

Jensen

BL

,

Marcussen

N

,

Skøtt

O

,

Bie

P

.

Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats

.

Nephrol Dial Transplant

.

2008

;

23

:

2777

–

83

.

88.

Mortensen

LA

,

Thiesson

HC

,

Tougaard

B

,

Egfjord

M

,

Fischer

ASL

,

Bistrup

C

.

The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)

.

BMC Nephrol

.

2018 May 3

;

19

(

1

):

105

.